Features pharmacotherapy of Diabetes Mellitus II type

N Tryshchuk

Автор(и)

N Tryshchuk National University of Pharmacy,

Ключові слова:

pharmacotherapy, diabetes mellitus II type

Анотація

Epidemiological increased incidence of diabetes mellitus is still ongoing. Treatment of patients with diabetes mellitus is challenging due to several factors: low level of diagnostics, difficulties in choice of drugs, the limited use of self-monitoring of glucose by patients, clinical failure medicines. Article defines the main groups of drugs that are needed for the treatment of diabetes mellitus type 2, based on the mechanism of action, dosage, side effects, contraindications and applications of algorithms. These articles will help to rationally choose hypoglycemic drugs for patients with diabetes mellitus type 2, thereby improving the condition of diabetics and reducing the risk of complications.

Посилання

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [Тext] / A. Patel [et al.] // N. Engl .J. Med. – 2008. – Vol. 358. – P. 2560–2572.

Meier, M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies [Тext] / M. Meier, M. Hummel // Journal: Vascular Health and Risk Management. – 2009. – Vol. 5. –P. 859-71

Vigersky, R.A. An overview of management issues in adult patients with type 2 diabetes mellitus [Тext] / R.A. Vigersky // J. Diabetes Sci. Technol. — 2011. —Vol. 5. — P. 245-250.

Dailey, G. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes [Тext] / G. Dailey // Clin. Ther. – 2011. – Iss. 33. –Vol. 6. – P. 665-78.

ADA Standards of medical care in diabetes–2011 [Тext] // Diabetes Care. – 2011. – Vol.34. – Suppl. 1. – P. 11–61.

Akalin, S. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control [Тext] / S. Akalin [et al.] // Int. J. Clin. Pract. – 2009. – Vol.63. – P.1421–1425.

Anderson, J.W. Importance of weight management in type 2 diabetes: review with metaanalysis of clinical studies [Тext] / J.W Anderson., C.W. Kendall, D.J. Jenkins // J. Am Coll. Nutr. – 2003. – Vol. 22. –Р. 331– 339.

Klein, S. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition [Тext] / S. Klein, N.F. Sheard, X. Pi-Sunyer [et al.] // Diabetes Care. – 2004. – Vol. 27. – Р. 2067–2073.

Nathan, D.M. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [Тext] /

D.M. Nathan, J.B. Buse, M.B. Davidson [et al.] // Diabetes Care. – 2009. – Vol. 32. – P.193–203.

Bryan, J. Insulin secretagogues, sulfonylurea

receptors and K (ATP) channels [Тext] / J. Bryan, A.

Crane, W.H. Vila-Carriles [et al.] // Curr. Pharm. Des. –

– Vol. 11. – Р. 2699–2716.

Avogaro, A. Treating diabetes today with gliclazide MR: a matter of numbers [Тext] / A. Avogaro // Diabetes Obes. Metab. – 2012. – Suppl. 1. – P. 14-9

Petunina, N.A. Individualnyiy podhod k lecheniyu bolnyih saharnyim diabetom 2-go tipa [Text] / N.A. Petunina, L.V. Truhina, E.I. Sinitsyina // RMZh . – 2013. – N.28. – S. 1412.

Algoritmy spetsializirovannoi meditsinskoi pomoshchi bolnym sakharnym diabetom [Тext] / I. I. Dedov, M.V. Shestakova.— [6-е izd.]. – М. – 2013.

Upravlenie saharnyim diabetom 2 tipa [Тext]/ M-vo zdravoohraneniya Habar. kraya, GOUDPO «In-t povyisheniya kvalifikatsii spetsialistov zdravoohraneniya», kaf. vnutr. bolezney; sost. Ushakova O.V. – Habarovsk: Izd. tsentr IPKSZ, 2010. –

s.

Nedosugova, L.V. Diagnostika i lechenie saharnogo diabeta 2 tipa [Тext]/ L.V. Nedosugova. – М., 2013.

Bailey, C. J. Metformin [Тext] / C.J. Bailey, R.C. Turner // N. Engl. J. Med. – 1996. – Vol. 334. –Р. 574– 579.

Lamanna, C. Effect of metformin on cardiovascular events and mortality: a metaanalysis of randomized clinical trials [Тext] / C. Lamanna, M. Monami, N. Marchionni [et al.] // Diabetes Obes. Metab. – 2011. - Vol.13. – Р. 221–228.

Dormandy, J. A. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial [Тext] / J. A. Dormandy, B. Charbonnel, D. J. Eckland [et al.] // Lancet. – 2005. – Vol. 366. – Р. 1279–1289.

Kahn, S.E. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [Тext] / S. E. Kahn, S. M. Haffner, M.A. Heise [et al.] // N. Engl. J. Med. – 2006. – Vol. 355. – Р. 2427–2443.

Van de Laar, F.A. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose [Тext] / F.A. Van de Laar, P.L. Lucassen, R.P. Akkermans [et al.] // Cochrane Database Syst . Rev. Issue 4. Art. No.: CD005061. doi:10.1002/14651858.CD005061. – Рub. 2 . – 2006.

Blonde, L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus [Тext] / L. Blonde // Am. J. Med. – 2010. – Vol. 123. – Р. 12-18.

Russell, S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction [Тext] / S. Russell // Int. J. Clin. Pharm. – 2013. – Iss. 35. – Vol.2.

– P. 159-72.

Jellinger, P.S. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes [Тext] / P.S. Jellinger // Postgrad. Med. – 2011. – Iss.123. – Vol.1. – P.53-65.

Russell-Jones, D. Recent advances in incretin-based therapies [Тext] / D. Russell-Jones, S. Gough // Clin .Endocrinol. (Oxf). – 2012. – Iss.77. – Vol.4. – P.489-99

Ametov, A.S. Pervyi ingibitor dipeptidilpeptidazy-IV sitagliptin: dostizhenie tseli v lechenii sakharnogo diabeta 2 tipa [Тext] / A.S. Ametov, E.V. Karpova // Endokrinologiya stolitsy: materialy VI moskovskogo gorodskogo syezda endokrinologov. – М. –2008. –S.28-

Pankiv, V.I. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-go tipa. Vozmozhnosti sitagliptina v dostizhenii kompensatsii sakharnogo diabeta 2-go tipa [Тext] / V.I. Pankiv // Mezhdunarodnyi endokrinologichesky zhurnal. –2011. –№6. –S.38.

Vikulova, O.K. Klinicheskaya effektivnost mimetika inkretinov eksenatida: rezultaty issledovany i pokazaniya k primeneniyu u bolnykh sakharnym diabetom tipa 2 [Тext] / O.K. Vikulova, M.V.

Shestakova // Consilium Medicum. – 2008. – № 10 (9). – S. 35–41.

Simonson, G.D. International Diabetes Center treatment of type 2 diabetes glucose algorithm [Тext] / G.D. Simonson, R.M. Cuddihy, D. Reader [et al.] // Diabetes Management. – 2011. - Vol.1. – Р. 175–189.

Bell, D. S. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II) [Тext] / D. S. Bell, M. Dharmalingam, S. Kumar [et al.] // Diabetes Obes. Metab. – 2011. –

Vol. 13. –Р. 800–805.

Zinman, B. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)

[Тext] / B. Zinman, J. Gerich, J.B. Buse [et al.] // Diabetes Care. – 2009. –Vol. 32. –Р. 1224–1230.

Yu, P.C. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes [Тext] / P.C. Yu, , Z. Bosnyak, A. Ceriello // Diabetes Res. Clin. Pract. – 2010. – Iss. 89. – Vol.1. – P.1-9.

Laakso, M. Glucose control in diabetes: which target level to aim for? [Text] / M. Laakso , H. Cederberg //J. Intern. Med. – 2012. –Vol. 272(1). – Р.1- 2.

Skyler, J.S. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes

Association and a scientific statement of the American

College of Cardiology Foundation and the American

Heart Association [Тext] / J.S. Skyler [ et al.]// Diabetes

Care. – 2009. – Vol. 32. –P. 187–192.